press release April 30, 2012, 8:44 a.m. EDT
COLORADO SPRINGS, Colo., Apr 30, 2012 (BUSINESS WIRE) — Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, was honored to be the Sponsor and an Exhibitor at the 7th national Patients Out of Time, medical cannabis conference in Tucson, Arizona. The conference was attended by patients, doctors, nurses, pharmacists, professors, supporters, and entrepreneurs of the medical cannabis industry. Our own Dr. Melamede presented patient’s results that we have documented at http://www.cannabisscience.com .
The University of California, San Francisco School of Medicine (UCSF) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Patients Out of Time is the only accredited CME program to educate medical professionals about cannabis as a medicine. There were over 25 world-renowned doctors and scientists sharing and presenting the latest research advances as the complexity of the endo-cannabinoid system continues to unfold. Please see the previous news release from April 17, 2012 at http://finance.yahoo.com/news/dr-robert-melamede-scheduled-speak-182800051.html
Speakers at the conference focused on the science and medicine of cannabinoids. Cannabis Science was overwhelmed, with great feedback by various representatives in the medical community. Prominent speakers included Dr. Robert Melamede, CEO and president of Cannabis Science; Dr. William Courtney of Cannabis Science’s scientific advisory board, and Dr. Andrew Weil, best selling author, speaker, and Integrative Medicine thought-leader. Talks covered specific ailments such as PTSD, cancer, and even drug addiction; research on cannabinoid science and medical applications, and law. Dr. Robert Melamede shared pictures show on our website. Cannabis Science helps cancer patients make informed choices regarding treatments. He also spoke as to the holistic nature by which the endocannabinoid system regulated homeostasis in all vertebrates from conception till death and therefore, why cannabis-based medicines are different from all others in their ability to help with so many illnesses.
Cannabis Science demonstrated a pre-release our multi-tiered, digital educational platform to be announced in more detail later this week. Our novel platform will help to meet the ever-expanding interest in cannabis that is coming from the medical communities as the almost miraculous medical benefits of cannabis emerge from the states that support medical marijuana. Our new educational platform (see below) will bring in revenues as we fill the emerging educational need of the medical community. Realistic cannabis education programs are not currently available in the professional schools that need them to end the disconnect between medical cannabis patients an their physicians.
At the conference the Cannabis Science booth collected data from attendees interested in Cannabis Science Stock and there was a lot of interest in our new branding platform.. Attendees were given PR Packets with CBIS information on cancer, Alzheimer’s, PTSD, aging, and heart disease. CBIS had attendees fill out a questionnaire to enter into a drawing for an iPad 3, a symbolic prize since Cannabis Science will launce our new digital education platform for Physicians, on the Apple iPad platform. Our congratulations to our conference iPad winner.
Andrew Pitsicalis, the Branding and Licensing Director for Cannabis Science, revealed the new digital platform and demonstrated the technology at the CBIS booth. Pitsicalis coordinated many interviews with Cannabis Planet TV, Arizona Clinics TV, The Phoenix Arizona Times, and local news and media. As a result, we had the honor to meet with a brain cancer survivor of an extremely dangerous surgery. In December of last year, he had a second operation to try to reduce the large mass in his brain. With stage 4 cancer, he came to Cannabis Science to help us create awareness for other cancer patients worldwide so that they too might understand there is hope with cannabis. The patient had not been a previous cannabis user, and was amazed at the impact the plant had on him. In fact, it prevented him from taking his own life, when he was no longer able to cope with having multiple grand mal seizures daily. The patients close friend begged him to smoke cannabis. When he did, he stopped having seizures. He told us he drove 7 hours to meet Dr. Robert Melamede because he was watching his videos our website and YouTube and found hope. The patient wanted to go to the conference to meet him and other doctors and scientists attending the conference.
The Patients Out of Time charity benefit dinner included entertainment by Greta Gaines from her upcoming album "Grassy Girl;" a live and silent auction, and a guest appearance by Gigi Ganjay. Greta’s information may be found at http://www.gretagaines.com , http://www.cannibuzz.com , and her reel at http://www.conlincasting.net/Gretareel/Greta_Gaines/Reel.html Greta Gaines is a client of Kaneabis (a Cannabis Science company).
If you would like to view information that Cannabis Science provided to the attendees of the conference, please visit our website.
Dr. Robert Melamede stated, "Things have never been better for Cannabis Science and this was confirmed at the conference this past weekend. Not only were we part of an historic event with Patients Out of Time, the amount of consciousness and knowledge gained by everyone attending will shape the medicinal science of the industry going forward. Furthermore, our network of professionals increased substantially as we continue to grow the Cannabis Science business model. Most importantly, this conference was a success because it was about the patients, and we heard dramatic testimonials from them, It was all about doing the right things, with the right people, for the right reasons."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE: Cannabis Science, Inc.
Cannabis Science Inc. Dr. Robert J. Melamede President & CEO 888-889-0888 [email protected] www.cannabisscience.com or Robert Kane Vice President of Investor Relations 561-234-6929 [email protected] www.cannabisscience.com CONTINUE READING...